| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 186.74% | HC Wainwright & Co. | → $40 | Reiterates | Buy → Buy |
| 10/12/2023 | 179.57% | UBS | $83 → $39 | Maintains | Buy |
| 10/11/2023 | 193.91% | JP Morgan | $62 → $41 | Maintains | Overweight |
| 10/11/2023 | 186.74% | HC Wainwright & Co. | $64 → $40 | Maintains | Buy |
| 10/11/2023 | 179.57% | Cantor Fitzgerald | $69 → $39 | Maintains | Overweight |
| 10/11/2023 | 136.56% | Morgan Stanley | $70 → $33 | Maintains | Overweight |
| 10/04/2023 | 394.62% | Cantor Fitzgerald | → $69 | Reiterates | Overweight → Overweight |
| 09/19/2023 | 394.62% | Cantor Fitzgerald | → $69 | Initiates Coverage On | → Overweight |
| 09/13/2023 | 330.11% | Evercore ISI Group | $50 → $60 | Maintains | Outperform |
| 09/05/2023 | 344.44% | JP Morgan | $49 → $62 | Maintains | Overweight |
| 08/28/2023 | 494.98% | UBS | → $83 | Initiates Coverage On | → Buy |
| 06/12/2023 | 401.79% | Morgan Stanley | $65 → $70 | Maintains | Overweight |
| 06/07/2023 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 05/17/2023 | 322.94% | Canaccord Genuity | $58 → $59 | Maintains | Buy |
| 05/16/2023 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 03/21/2023 | 315.77% | Canaccord Genuity | $50 → $58 | Maintains | Buy |
| 03/20/2023 | 358.78% | HC Wainwright & Co. | → $64 | Reiterates | → Buy |
| 01/27/2023 | 365.95% | Morgan Stanley | → $65 | Upgrades | Equal-Weight → Overweight |
| 11/07/2022 | 186.74% | Morgan Stanley | $30 → $40 | Maintains | Equal-Weight |
| 11/07/2022 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/14/2022 | 115.05% | Morgan Stanley | $26 → $30 | Maintains | Equal-Weight |
| 09/14/2022 | 258.42% | Evercore ISI Group | $10 → $50 | Upgrades | In-Line → Outperform |
| 11/15/2021 | 107.89% | Morgan Stanley | $27 → $29 | Maintains | Equal-Weight |
| 11/15/2021 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
| 10/19/2021 | 93.55% | Morgan Stanley | → $27 | Downgrades | Overweight → Equal-Weight |
| 09/10/2021 | 186.74% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 08/16/2021 | 358.78% | HC Wainwright & Co. | $68 → $64 | Maintains | Buy |
| 03/23/2021 | 351.61% | Morgan Stanley | $70 → $63 | Maintains | Overweight |
| 03/23/2021 | 387.46% | HC Wainwright & Co. | $61 → $68 | Maintains | Buy |
| 03/18/2021 | 229.75% | Canaccord Genuity | $51 → $46 | Maintains | Buy |
| 03/17/2021 | 480.65% | Chardan Capital | $79 → $81 | Maintains | Buy |
| 03/17/2021 | 337.28% | HC Wainwright & Co. | $64 → $61 | Maintains | Buy |
| 02/26/2021 | 287.1% | Guggenheim | → $54 | Initiates Coverage On | → Buy |
| 11/13/2020 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
| 09/10/2020 | 401.79% | Morgan Stanley | → $70 | Initiates Coverage On | → Overweight |
| 07/20/2020 | 344.44% | HC Wainwright & Co. | $45 → $62 | Maintains | Buy |
| 07/07/2020 | 466.31% | Chardan Capital | → $79 | Initiates Coverage On | → Buy |
| 07/01/2020 | 222.58% | HC Wainwright & Co. | $33 → $45 | Maintains | Buy |
| 07/01/2020 | 244.09% | Jefferies | $31 → $48 | Maintains | Buy |
| 03/02/2020 | 136.56% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 02/10/2020 | 158.06% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
| 07/15/2019 | 100.72% | JP Morgan | → $28 | Initiates Coverage On | → Overweight |
| 07/15/2019 | 143.73% | Roth Capital | → $34 | Initiates Coverage On | → Buy |
| 07/15/2019 | 100.72% | Jefferies | → $28 | Initiates Coverage On | → Buy |
What is the target price for Akero Therapeutics (AKRO)?
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $40.00 expecting AKRO to rise to within 12 months (a possible 186.74% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
The latest analyst rating for Akero Therapeutics (NASDAQ: AKRO) was provided by HC Wainwright & Co., and Akero Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a reiterated with a price target of $0.00 to $40.00. The current price Akero Therapeutics (AKRO) is trading at is $13.95, which is within the analyst's predicted range.